02/19/2025
3:32 PM | Eagle Pharmaceuticals (Subject)
Nantahala Capital Management, LLC (Filed by)
| Form SCHEDULE 13G/A | |
02/19/2025
3:32 PM | Eagle Pharmaceuticals (Subject)
Nantahala Capital Partners Limited Partnership (Filed by)
| Form SCHEDULE 13G | |
02/14/2025
8:01 AM | Eagle Pharmaceuticals (Subject)
Union Square Park Capital Management, LLC (Filed by)
| Form SCHEDULE 13G/A | |
12/09/2024
11:15 PM | Eagle Pharmaceuticals (Filer)
| Form EFFECT | |
12/02/2024
3:17 PM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/27/2024
3:05 PM | Eagle Pharmaceuticals (Filer)
| Form S-8 POS | |
11/27/2024
3:06 PM | Eagle Pharmaceuticals (Filer)
| Form S-8 POS | |
11/27/2024
3:06 PM | Eagle Pharmaceuticals (Filer)
| Form S-8 POS | |
11/27/2024
3:07 PM | Eagle Pharmaceuticals (Filer)
| Form S-8 POS | |
11/27/2024
3:07 PM | Eagle Pharmaceuticals (Filer)
| Form S-8 POS | |
11/27/2024
3:07 PM | Eagle Pharmaceuticals (Filer)
| Form S-8 POS | |
Get the Latest News and Ratings for EGRX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. |
11/27/2024
3:08 PM | Eagle Pharmaceuticals (Filer)
| Form POS AM | |
11/27/2024
3:08 PM | Eagle Pharmaceuticals (Filer)
| Form RW | |
11/27/2024
8:25 AM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/19/2024
6:59 PM | Eagle Pharmaceuticals (Issuer)
Krawtschuk Christopher (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
11/15/2024
4:19 PM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
10:34 AM | BRANDES INVESTMENT PARTNERS, LP (Filed by)
Eagle Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/14/2024
9:25 AM | Eagle Pharmaceuticals (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
| Form SC 13G/A | |
11/13/2024
7:30 AM | Eagle Pharmaceuticals (Filer)
| Form NT 10-Q | |
11/12/2024
6:08 AM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/05/2024
3:32 PM | Eagle Pharmaceuticals (Subject)
Nantahala Capital Management, LLC (Filed by)
| Form SC 13G/A | |
10/31/2024
12:36 PM | Eagle Pharmaceuticals (Subject)
Union Square Park Capital Management, LLC (Filed by)
| Form SC 13G/A | |
10/31/2024
7:50 AM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/09/2024
3:05 PM | Eagle Pharmaceuticals (Subject)
HIRSCHMAN ORIN (Filed by)
| Form SC 13G/A | |
10/08/2024
11:42 AM | Eagle Pharmaceuticals (Subject)
Union Square Park Capital Management, LLC (Filed by)
| Form SC 13G | |
10/02/2024
8:00 AM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/27/2024
3:30 PM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/09/2024
3:35 PM | Eagle Pharmaceuticals (Filer)
| Form NT 10-Q | |
08/05/2024
8:03 AM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/10/2024
7:00 AM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/08/2024
3:32 PM | BlackRock Inc. (Filed by)
Eagle Pharmaceuticals (Subject)
| Form SC 13G/A | |
07/03/2024
1:02 PM | Eagle Pharmaceuticals (Subject)
Nantahala Capital Management, LLC (Filed by)
| Form SC 13G | |
05/29/2024
7:20 AM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/22/2024
8:08 AM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/15/2024
8:29 AM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/10/2024
4:27 PM | Eagle Pharmaceuticals (Filer)
| Form NT 10-Q | |
04/12/2024
3:16 PM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/12/2024
3:16 PM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/18/2024
7:37 PM | Eagle Pharmaceuticals (Subject)
Tarriff Scott (Filed by)
| Form SC 13G/A | |
03/18/2024
7:00 AM | Eagle Pharmaceuticals (Filer)
| Form NT 10-K | |
03/08/2024
3:49 PM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry." (Ad) If you missed out on the big boom in Nvidia…
Listen up, because according to Nvidia's own CEO…
Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry. You MUST act before March 17th. |
03/01/2024
3:40 PM | Eagle Pharmaceuticals (Issuer)
Tarriff Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/01/2024
6:35 AM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/29/2024
7:23 PM | Cahill Brian Joseph (Reporting)
Eagle Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
3:44 PM | Eagle Pharmaceuticals (Issuer)
Tarriff Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
7:09 AM | Eagle Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
